参考文献

［1］SKORECKI K, CHERTOW G M, MARSDEN P A, et al. Brenner and Rector′s The Kidney [M]. 10th ed. Elsevier,2016.

［2］PENFOLD R S, PRENDECKI M, MCADOO S, et al. Primary IgA nephropathy: current challenges and future prospects [J]. Int J Nephrol Renovasc Dis, 2018,11: 137-148.

［3］LISZEWSKI M K, JAVA A, SCHRAMM E C, et al. Complement dysregulation and disease: insights from contemporary genetics [J]. Annu Rev Pathol, 2017, 24(12): 25-52.

［4］CHEN S F, CHEN M. Complement activation in progression of chronic kidney disease [J]. Adv Exp Med Biol, 2019, 1165: 423-441.

［5］ZUO C, ZHU Y. An update to the pathogenesis for monoclonal gammopathy of renal significance [J]. Crit Rev Oncol Hematol, 2020, 149: 102926.

［6］LEUNG N, DROSOU M E, NASR S H. Dysproteinemias and glomerular disease [J]. Clin J Am Soc Nephrol, 2018,13 (1): 128-139.

［7］CARA-FUENTES G, CLAPP W L, JOHNSON R J, et al. Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms [J]. Pediatr Nephrol,2016, 31 (12): 2179-2189.

［8］RADHAKRISHNAN J, PERAZELLA M A. Drug-induced glomerular disease: attention required! [J]. Clin J Am Soc Nephrol, 2015, 10 (7): 1287-1290.

［9］RUBIN R L. Drug-induced lupus [J]. Expert Opin Drug Saf, 2015, 14 (3): 361-378.

［10］SIEVERS L K, ECKARDT K U. Molecular mechanisms of kidney injury and repair in arterial hypertension [J]. Int J Mol Sci, 2019, 20 (9): 2138.

［11］SUN H J. Current opinion for hypertension in renal fibrosis [J]. Adv Exp Med Biol, 2019, 1165: 37-47.

［12］SECCIA T, CAROCCIA B, PIAZZA M, et al. The key role of epithelial to mesenchymal transition (emt) in hypertensive kidney disease [J]. Int J Mol Sci, 2019, 20(14): 3567.

［13］RAO V, TAN S H, CANDASAMY M, et al. Diabetic nephropathy: An update on pathogenesis and drug development [J]. Diabetes Metab Syndr, 2019, 13 (1):754-762.

［14］ZENG L F, XIAO Y, SUN L. A Glimpse of the Mechanisms Related to Renal Fibrosis in Diabetic Nephropathy [J]. Adv Exp Med Biol. 2019, 1165: 49-79.

［15］GAI Z B, WANG T Q, VISENTIN M, et al. Lipid Accumulation and Chronic Kidney Disease [J]. Nutrients. 2019, 11 (4): 722.

［16］ROSNER M H, PERAZELLA M A. Acute kidney injury in the patient with cancer [J]. Kidney Res Clin Pract, 2019, 38 (3): 295-308.

［17］MEHTA L, JIM B. Hereditary Renal Diseases [J]. Semin Nephrol. 2017, 37 (4): 354-361.

［18］SETHI S, HAAS M, MARKOWITZ G S, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN [J]. J Am Soc Nephrol, 2016, 27 (5): 1278-1287.

［19］MALLIPATTU S K, HE J C. The podocyte as a direct target for treatment of glomerular disease? [J]. Am J Physiol Renal Physiol, 2016, 311 (1): F46-F51.

［20］MIMA A, YASUZAWA T, NAKAMURA T. Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes [J]. Sci Rep,2020, 10 (1): 5775.